HDCN Abstract:  ASN Annual Meeting -- San Francisco  

Niwa T, Adijiang A, Goto S, et al.

Indoxyl Sulfate, a Uremic Toxin, Promotes Aortic Calcification with Expression of Osteoblast-Specific Proteins.

ASN Annual Meeting -- San Francisco
J Am Soc Nephrol (Nov) 18:640A 2007

Purpose: End-stage renal disease (ESRD) is associated with progression of arteriosclerosis. The aim of this study was to determine if the administration of indoxyl sulfate (IS), a uremic toxin, stimulates the progression of arteriosclerosis.

Methods: The rat groups consisted of: 1) Dahl salt-resistant normotensive rats (DR) with intake of 0.3% salt, 2) Dahl salt-sensitive hypertensive rats (DS) with intake of 2.0% salt, 3) Dahl salt-sensitive hypertensive IS-administered rats (DS-IS) with intake of 2.0% salt and 200 mg/kg of IS in water. After 30 weeks, severe vascular calcification was observed by von Kossa staining in the arcuate aorta of all the DS-IS rats, but hardly in DS or DR rats.

Results: Immunohistochemistry demonstrated that osteopontin, core binding factor 1 (Cbfa1), alkaline phosphatase (ALP), osteocalcin, IS, and organic anion transporter (OAT) 3 were colocalized in the cells embedded in the aortic calcification area of DS-IS rats. Aortic wall thickness was significantly increased in arcuate, thoracic, and abdominal aortas of DS-IS rats compared with DS and DR rats.

Conclusion: IS promoted not only aortic wall thickening but also aortic calcification with expression of osteoblast- specific proteins. Thus, IS is a vascular toxin that may contribute to the progression of arteriosclerosis in ESRD.

© Copyright 2007-2008, American Society of Nephrology. Reproduced with permission.
Until September of 2008, all ASN abstracts from the 2007 Annual Meeting are available at this link

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.